Bisphosphonates for osteoporosis in nonmetastatic prostate cancer patients receiving androgen-deprivation therapy: A systematic review and meta-analysis

Asian Pacific Journal of Cancer Prevention

Volumn 14, Issue 5, 2013, Pages 3337-3343

  Ding, Hui ^a   Yang, Li ^a   Du, Wan ^b   Teng, Yang ^c   Fu, Sheng Jun ^a   Tao, Yan ^a   Lu, Jian Zhong ^a   Wang, Zhi Ping ^a  

^a Key Laboratory of Combating Desertification Gansu Province   (China)

^b LANZHOU UNIVERSITY   (China)

^c PEOPLE S HOSPITAL OF RIZHAO   (China)

Author keywords

Androgen deprivation therapy; Bisphosphonates; Meta analysis; Osteoporosis; Prostate cancer

Indexed keywords

ANTIANDROGEN; BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT;

AGED; BONE DENSITY; BONE DISEASES, METABOLIC; DRUG EFFECTS; FEMUR; FRACTURES, BONE; HIP; HUMAN; LUMBAR VERTEBRA; MALE; META ANALYSIS; OSTEOPOROSIS; PATHOLOGY; PHYSIOLOGY; PROSTATIC NEOPLASMS; TREATMENT OUTCOME;

AGED; ANDROGEN ANTAGONISTS; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; BONE DISEASES, METABOLIC; DIPHOSPHONATES; FEMUR; FRACTURES, BONE; HIP; HUMANS; LUMBAR VERTEBRAE; MALE; OSTEOPOROSIS; PROSTATIC NEOPLASMS; TREATMENT OUTCOME;

EID: 84880339604     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2013.14.5.3337     Document Type: Article

References (31)

1. Adler RA (2011). Management of osteoporosis in men onandrogen deprivation therapy. Maturitas, 68, 143-7.
2. Balasch J (2003). Sex steroids and bone: current perspectives. Hum Reprod Update, 9, 207-22.
3. Bhoopalam N, Campbell SC, Moritz T, et al (2009). Intravenous zoledronic acid to prevent osteoporosis in a veteran population with multiple risk factors for bone loss on androgen deprivation therapy. J Urol, 182, 2257-64.
4. Bolla M (1999). Adjuvant hormonal treatment with radiotherapy for locally advanced prostate cancer. Eur Urol, 35, 23-5.
5. Brufsky AM (2008). Cancer treatment-induced bone loss: pathophysiology and clinical perspectives. Oncologist, 13, 187-95.
6. Casey R, Gesztesi Z, Rochford J (2010). Long term zoledronic acid during androgen blockade for prostate cancer. Can J Urol, 17, 5170-7.
7. Eriksson S, Eriksson A, Stege R, et al (1995). Bone mineral density in patients with prostatic cancer treated with orchidectomy and with estrogens. Calcif Tissue Int, 57, 97-9.
8. Frydenberg M, Stricker PD, Kaye KW (1997). Prostate cancer diagnosis and management. Lancet, 349, 1681-7.
9. Greenspan SL, Nelson JB, Trump DL, et al (2007). Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer: a randomized trial. Ann Intern Med, 146, 416-24.
10. Grivas N, Hastazeris K, Kafarakis V, et al (2012). Prostate cancer epidemiology in a rural area of North Western Greece. Asian Pac J Cancer Prev, 13, 999-1002.
11. Higano CS (2004). Understanding treatments for bone loss and bone metastases in patients with prostate cancer: a practical review and guide for the clinician. Urol Clin North Am, 31, 331-52.
12. Higano CS (2008). Androgen-deprivation-therapy-induced fractures in men with nonmetastatic prostate cancer: what do we really know Nat Clin Pract Urol, 5, 24-34.
13. Israeli RS, Rosenberg SJ, Saltzstein DR, et al (2007). The effect of zoledronic acid on bone mineral density in patients undergoing androgen deprivation therapy. Clin Genitourin Cancer, 5, 271-7.
14. Jemal A, Siegel R, Ward E, et al (2009). Cancer statistics, 2009. CA Cancer J Clin, 59, 225-49.
15. Magno C, Anastasi G, Morabito N, et al (2005). Preventing bone loss during androgen deprivation therapy for prostate cancer: early experience with neridronate. Eur Urol, 47, 575-80.
16. Maillefert JF, Sibilia J, Michel F, et al (1999). Bone mineral density in men treated with synthetic gonadotropin-releasing hormone agonists for prostatic carcinoma. J Urol, 161, 1219-22.
17. Manolagas SC, Kousteni S, Jilka RL (2002). Sex steroids and bone. Recent Prog Horm Res, 57, 385-409.
18. Messing EM, Manola J, Sarosdy M, et al (1999). Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med, 341, 1781-8.
19. Michaelson MD, Kaufman DS, Lee H, et al (2007). Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer. J Clin Oncol, 25, 1038-42.
20. Michaud LB (2010). Managing cancer treatment-induced bone loss and osteoporosis in patients with breast or prostate cancer. Am J Health Syst Pharm, 67, S20-30.
21. Morabito N, Gaudio A, Lasco A, et al (2004). Neridronate prevents bone loss in patients receiving androgen deprivation therapy for prostate cancer. J Bone Miner Res, 19, 1766-70.
22. Riggs BL, Khosla S, Melton LJ, 3rd (2002). Sex steroids and the construction and conservation of the adult skeleton. Endocr Rev, 23, 279-302.
23. Ryan CW, Huo D, Demers LM, et al (2006). Zoledronic acid initiated during the first year of androgen deprivation therapy increases bone mineral density in patients with prostate cancer. J Urol, 176, 972-8.
24. Ryan CW, Huo D, Bylow K, et al (2007). Suppression of bone density loss and bone turnover in patients with hormonesensitive prostate cancer and receiving zoledronic acid. BJU Int, 100, 70-5.
25. Serpa NA, Tobias-Machado M, Esteves MA, et al (2010). A systematic review and meta-analysis of bone metabolism in prostate adenocarcinoma. BMC Urol, 10, 9.
26. SharifiN, Gulley J L, Dahut W L (2005). Androgen deprivation therapy for prostate cancer. Jama, 294, 238-44.
27. Smith MR, McGovern FJ, Zietman AL, et al (2001). Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med, 345, 948-55.
28. Smith MR, Eastham J, Gleason DM, et al (2003). Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol, 169, 2008-12.
29. Smith MR, Saad F, Egerdie B, et al (2009). Effects of denosumab on bone mineral density in men receiving androgen deprivation therapy for prostate cancer. J Urol, 182, 2670-5.
30. Smith MR, Morton RA, Barnette KG, et al (2010). Toremifene to reduce fracture risk in men receiving androgen deprivation therapy for prostate cancer. J Urol, 184, 1316-21.
31. Taxel P, Dowsett R, Richter L, et al (2010). Risedronate prevents early bone loss and increased bone turnover in the first 6 months of luteinizing hormone-releasing hormone-agonist therapy for prostate cancer. BJU Int, 106, 1473-6.